China's National Medical Products Administration has approved Neuracle Technology's brain implant, called NEO, for public use beyond clinical trials, making it the first commercial brain-computer interface to reach patients outside of limited research settings, according to multiple reports.
The Shanghai-based startup's coin-sized device is designed to help patients who are paralyzed due to spinal cord injuries. One patient, Dong Hui, was profiled by MIT Technology Review after 11 months using the implant. Before receiving NEO, Dong suffered a spinal cord injury in a car accident six years ago and could barely move his arms or use his fingers. After treatment, he can now write his name.
NEO sensors are placed on the outside membrane of the brain, with signals transmitted by a computer implant resting on the skull that moves a robotic glove helping the hand relearn signal reception from the brain. Dong told MIT that on the ninth day of training, his right hand successfully grabbed a ball without the glove assistance. 'That was a miraculous moment,' he said. Neuracle conducted clinical trials with 36 subjects, with 32 occurring in the past year.
The approval comes as China has identified brain-computer interfaces as one of six strategic technology sectors critical to its future, alongside quantum technology, biomanufacturing, hydrogen and nuclear fusion power, artificial intelligence, and 6G mobile communications. The country announced $165 million to fund startups through research to commercialization.
What the Left Is Saying
Progressive policy advocates point to China's approval as evidence that the United States risks ceding ground in critical emerging technologies without coordinated government investment. They argue that while private companies like Neuralink advance innovation, public funding and streamlined regulatory pathways—similar to China's approach with national health insurance integration—could accelerate American breakthroughs.
Tech policy researchers at progressive think tanks have noted that the U.S. Food and Drug Administration's rigorous approval process, while ensuring safety, may place American companies at a competitive disadvantage against nations willing to move faster on emerging medical devices. Some advocates for patients with spinal cord injuries argue that quicker access through programs like national health insurance could benefit Americans waiting for treatment options.
What the Right Is Saying
Conservative commentators and free-market advocates contend that Neuralink's approach offers technological advantages despite arriving later to market. They note that Neuralink penetrates the brain's protective membrane, allowing direct interface with individual neurons—a design some researchers argue enables deeper biological connection and more precise signal collection than NEO's less invasive approach.
Seniors in Republican policy circles have emphasized that American companies operate under stricter regulatory scrutiny from the FDA, ensuring patient safety standards that may be lower in other markets. They argue this reflects a deliberate choice to prioritize long-term safety over speed. Additionally, supporters of private enterprise note that Synchron, backed by investors including Jeff Bezos and Bill Gates, raised $200 million in late 2025—demonstrating continued investor confidence in the U.S. brain-computer interface ecosystem.
What the Numbers Show
The global brain-computer interface market is projected to reach $1.7 billion by 2035, according to industry analyses cited in multiple reports. Neuracle Technology's clinical trials involved 36 subjects with 32 procedures completed in the past year alone—indicating rapid scaling of their surgical program. Neuralink has not yet received commercial approval from any regulatory body despite its longer development timeline.
China has committed $165 million specifically toward brain-computer interface startups through research, development, and commercialization stages. Synchron's late 2025 funding round totaled $200 million. These figures illustrate the significant capital flowing into competing BCI programs across multiple nations.
The Bottom Line
Neuracle Technology's commercial approval marks a milestone in the global race to bring brain-computer interfaces from laboratory concept to patient treatment. China's integration of the technology into its national health insurance system could enable faster scaling than competitors relying on commercial markets alone. Meanwhile, Neuralink has announced plans for a significant expansion of clinical trials in 2026 and is developing less invasive surgical techniques that would allow electrodes to pass through the dura mater without removal—potentially narrowing the safety advantage NEO currently holds. How quickly U.S. regulators move relative to their Chinese counterparts could determine whether American companies catch up commercially or remain behind in this emerging medical technology sector.